دورية أكاديمية
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
| العنوان: | Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis. |
|---|---|
| المؤلفون: | Nijhuis L; Laboratory of Translational Immunology, Department of Pediatric Immunology & Rheumatology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands., Peeters JGC; Laboratory of Translational Immunology, Department of Pediatric Immunology & Rheumatology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands., Vastert SJ; Laboratory of Translational Immunology, Department of Pediatric Immunology & Rheumatology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands., van Loosdregt J; Laboratory of Translational Immunology, Department of Pediatric Immunology & Rheumatology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands. |
| المصدر: | Frontiers in immunology [Front Immunol] 2019 Feb 07; Vol. 10, pp. 151. Date of Electronic Publication: 2019 Feb 07 (Print Publication: 2019). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Arthritis, Juvenile/*drug therapy , Histone Deacetylase Inhibitors/*therapeutic use , T-Lymphocytes/*immunology, Acetylation ; Animals ; Arthritis, Juvenile/immunology ; Chronic Disease ; Histones/immunology ; Humans ; Immune Tolerance ; Inflammation/drug therapy |
| مستخلص: | Juvenile Idiopathic Arthritis (JIA) is characterized by a loss of immune tolerance. Here, the balance between the activity of effector T (Teff) cells and regulatory T (Treg) cells is disturbed resulting in chronic inflammation in the joints. Presently, therapeutic strategies are predominantly aimed at suppressing immune activation and pro-inflammatory effector mechanisms, ignoring the opportunity to also promote tolerance by boosting the regulatory side of the immune balance. Histone deacetylases (HDACs) can deacetylate both histone and non-histone proteins and have been demonstrated to modulate epigenetic regulation as well as cellular signaling in various cell types. Importantly, HDACs are potent regulators of both Teff cell and Treg cell function and can thus be regarded as attractive therapeutic targets in chronic inflammatory arthritis. HDAC inhibitors (HDACi) have proven therapeutic potential in the cancer field, and are presently being explored for their potential in the treatment of autoimmune diseases. Specific HDACi have already been demonstrated to reduce the secretion of pro-inflammatory cytokines by Teff cells, and promote Treg numbers and suppressive capacity in vitro and in vivo . In this review, we outline the role of the different classes of HDACs in both Teff cell and Treg cell function. Furthermore, we will review the effect of different HDACi on T cell tolerance and explore their potential as a therapeutic strategy for the treatment of oligoarticular and polyarticular JIA. |
| References: | Gastroenterology. 2010 Feb;138(2):583-94. (PMID: 19879272) Mol Cell Biol. 2011 May;31(10):2066-78. (PMID: 21444725) Nat Med. 2001 Apr;7(4):437-43. (PMID: 11283670) Mol Cell Biol. 2006 Apr;26(8):3106-13. (PMID: 16581785) Int J Biochem Cell Biol. 2009 Jan;41(1):185-98. (PMID: 18804549) Cancer Lett. 2001 May 10;166(1):55-64. (PMID: 11295287) J Immunol. 2016 Jul 15;197(2):541-54. (PMID: 27279370) J Immunol. 2010 Sep 15;185(6):3489-97. (PMID: 20702731) Sci Signal. 2012 Jun 19;5(229):ra45. (PMID: 22715468) Blood. 2013 Feb 21;121(8):1335-44. (PMID: 23287868) J Rheumatol. 2009 Aug;36(8):1580-9. (PMID: 19531758) Nature. 2004 May 27;429(6990):457-63. (PMID: 15164071) J Biol Chem. 2011 Aug 19;286(33):28833-43. (PMID: 21708950) Nat Genet. 2001 Jan;27(1):20-1. (PMID: 11137993) Cell Rep. 2015 Sep 29;12(12):1986-96. (PMID: 26387944) Ann Rheum Dis. 2017 Jan;76(1):277-285. (PMID: 27457515) Bull NYU Hosp Jt Dis. 2006;64(1-2):72-6. (PMID: 17121494) Nat Rev Rheumatol. 2013 Jan;9(1):34-42. (PMID: 23390638) Sci Rep. 2017 Jun 20;7(1):3853. (PMID: 28634345) Diabetes Metab Res Rev. 2008 Feb;24(2):115-22. (PMID: 17918277) Diabetologia. 2000 Nov;43(11):1337-45. (PMID: 11126400) Rheumatology (Oxford). 2010 Aug;49(8):1447-60. (PMID: 20421217) Anticancer Res. 2000 May-Jun;20(3A):1471-85. (PMID: 10928059) Nat Rev Drug Discov. 2006 Sep;5(9):769-84. (PMID: 16955068) Trends Immunol. 2011 Jul;32(7):335-43. (PMID: 21570914) Clin Epigenetics. 2012 Feb 27;4(1):4. (PMID: 22414433) Nat Med. 2007 Nov;13(11):1299-307. (PMID: 17922010) J Immunol. 2011 Apr 15;186(8):4782-93. (PMID: 21398603) Mol Med. 2011 May-Jun;17(5-6):397-403. (PMID: 21308151) Cell Mol Immunol. 2012 Sep;9(5):390-8. (PMID: 22922441) Biochem J. 2003 Mar 15;370(Pt 3):737-49. (PMID: 12429021) J Immunol. 2004 May 15;172(10):6435-43. (PMID: 15128835) Ann Rheum Dis. 2011 Oct;70(10):1866-73. (PMID: 21742641) ACS Med Chem Lett. 2015 Oct 05;6(11):1156-61. (PMID: 26617971) Acta Pharmacol Sin. 2006 Jun;27(6):724-7. (PMID: 16723091) Shock. 2009 Nov;32(5):517-23. (PMID: 19295477) Immunol Rev. 2006 Aug;212:8-27. (PMID: 16903903) Mol Cell Biol. 2007 Jul;27(14):5184-200. (PMID: 17470548) Arthritis Rheum. 2013 Dec;65(12):3279-84. (PMID: 23983021) Med Res Rev. 2006 Jul;26(4):397-413. (PMID: 16450343) Arthritis Rheum. 2013 Mar;65(3):552-4. (PMID: 23280009) Osteoarthritis Cartilage. 2013 Mar;21(3):470-80. (PMID: 23257246) Rheumatology (Oxford). 2009 Jun;48(6):602-6. (PMID: 19269955) Blood. 2013 Mar 14;121(11):2038-50. (PMID: 23327920) Lancet. 2004 Mar 20;363(9413):925-31. (PMID: 15043959) Arthritis Res Ther. 2018 Jul 20;20(1):148. (PMID: 30029685) Immunity. 2016 Jun 21;44(6):1337-49. (PMID: 27317260) Blood. 2011 Sep 29;118(13):3538-48. (PMID: 21828127) Mol Cell Biol. 2015 Nov;35(22):3854-65. (PMID: 26324326) EMBO J. 2012 Nov 28;31(23):4453-65. (PMID: 23103766) Mol Med. 2011 May-Jun;17(5-6):353-62. (PMID: 21365126) JAMA. 2010 Apr 7;303(13):1266-73. (PMID: 20371785) Annu Rev Biochem. 2007;76:75-100. (PMID: 17362198) Arthritis Rheumatol. 2014 Nov;66(11):3160-9. (PMID: 25077692) Mol Med. 2005 Jan-Dec;11(1-12):1-15. (PMID: 16557334) Arthritis Rheum. 2000 Apr;43(4):765-74. (PMID: 10765921) Cell. 2001 Oct 19;107(2):149-59. (PMID: 11672523) Baillieres Clin Rheumatol. 1998 May;12(2):245-71. (PMID: 9890097) J Intern Med. 2005 Aug;258(2):94-114. (PMID: 16018787) Blood. 2006 Feb 15;107(4):1696-702. (PMID: 16263787) Arthritis Rheumatol. 2016 Jan;68(1):229-36. (PMID: 26360332) Annu Rev Biochem. 1977;46:931-54. (PMID: 332067) Arthritis Res Ther. 2017 Jul 3;19(1):154. (PMID: 28673326) Science. 2009 Aug 14;325(5942):834-40. (PMID: 19608861) Sci Rep. 2017 Aug 17;7(1):8626. (PMID: 28819166) J Med Chem. 2012 Jan 26;55(2):639-51. (PMID: 22165909) Mol Cell. 2006 Aug 4;23(3):289-96. (PMID: 16885019) Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):715-21. (PMID: 20823773) J Clin Invest. 2015 Mar 2;125(3):1111-23. (PMID: 25642770) J Rheumatol. 2007 May;34(5):1133-8. (PMID: 17343315) Mol Cancer Ther. 2003 Feb;2(2):151-63. (PMID: 12589032) Diabetes. 1998 Jun;47(6):980-4. (PMID: 9604880) Biochem Biophys Res Commun. 2004 Apr 30;317(2):463-71. (PMID: 15063780) J Nutr. 2003 Jul;133(7 Suppl):2485S-2493S. (PMID: 12840228) J Autoimmun. 2018 Jan;86:51-61. (PMID: 28964722) Cell. 2000 May 26;101(5):455-8. (PMID: 10850488) J Clin Invest. 2009 Oct;119(10):3048-58. (PMID: 19729833) Arthritis Rheum. 2012 Feb;64(2):418-22. (PMID: 21952924) PLoS One. 2008 May 28;3(5):e2321. (PMID: 18509529) Blood. 2010 Feb 4;115(5):965-74. (PMID: 19996091) Theranostics. 2017 Feb 23;7(4):1002-1009. (PMID: 28382171) Blood. 2015 Jan 29;125(5):815-9. (PMID: 25428224) Am J Transplant. 2018 Jul;18(7):1596-1603. (PMID: 29603600) Arthritis Rheum. 2008 Mar;58(3):875-87. (PMID: 18311821) Int J Cancer. 2016 May 15;138(10):2477-86. (PMID: 26704363) Nat Genet. 2001 Jan;27(1):18-20. (PMID: 11137992) Clin Immunol. 2014 Mar;151(1):29-42. (PMID: 24503172) EMBO J. 2002 Nov 15;21(22):6236-45. (PMID: 12426395) Curr Opin Immunol. 2017 Dec;49:64-70. (PMID: 29065384) Nat Rev Rheumatol. 2011 Jun 07;7(7):416-26. (PMID: 21647204) Acta Pharmacol Sin. 2012 May;33(5):668-74. (PMID: 22447223) Ann Pharmacother. 2012 Oct;46(10):1340-8. (PMID: 22968522) J Immunol. 2015 Aug 15;195(4):1578-90. (PMID: 26163592) Arthritis Rheum. 2009 Jul;60(7):2113-23. (PMID: 19565504) Best Pract Res Clin Rheumatol. 2017 Aug;31(4):460-475. (PMID: 29773267) Mol Med. 2011 May-Jun;17(5-6):391-6. (PMID: 21327299) Nat Rev Genet. 2009 Jan;10(1):32-42. (PMID: 19065135) Rheumatology (Oxford). 2015 Sep;54(9):1724-34. (PMID: 25877908) Mol Cell Biol. 2011 Mar;31(5):1022-9. (PMID: 21199917) Nature. 2000 Nov 16;408(6810):377-81. (PMID: 11099047) J Immunol. 2010 Mar 1;184(5):2718-28. (PMID: 20100935) Nature. 2015 Feb 19;518(7539):337-43. (PMID: 25363779) J Rheumatol. 2008 May;35(5):804-10. (PMID: 18398941) Eur J Endocrinol. 2004 May;150(5):719-24. (PMID: 15132730) Science. 2012 Sep 7;337(6099):1190-5. (PMID: 22955828) Can Med Assoc J. 1959 Aug 15;81:235-8. (PMID: 14402370) Diabetes Res Clin Pract. 2006 Mar;71(3):320-33. (PMID: 16233932) Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. (PMID: 27713375) Ann Rheum Dis. 2016 Jun;75(6):1092-8. (PMID: 25985972) Blood. 2011 Mar 31;117(13):3658-68. (PMID: 21292776) Oncotarget. 2017 Mar 14;8(11):17562-17572. (PMID: 28177888) J Immunol. 1995 Aug 1;155(3):1151-64. (PMID: 7636184) Crit Rev Immunol. 2011;31(3):233-63. (PMID: 21740352) Blood. 2017 Jul 13;130(2):146-155. (PMID: 28550044) Exp Hematol. 2016 May;44(5):315-21. (PMID: 26923266) Lancet Oncol. 2014 Jan;15(1):87-95. (PMID: 24295572) Exp Mol Pathol. 2009 Oct;87(2):99-104. (PMID: 19577564) Diabet Med. 2006 Aug;23(8):920-3. (PMID: 16911633) J Biol Chem. 2011 Jun 24;286(25):22211-8. (PMID: 21531716) Autoimmun Rev. 2011 Jun;10(8):482-9. (PMID: 21320644) Front Immunol. 2018 Jul 06;9:1525. (PMID: 30034392) Kidney Int. 2016 May;89(5):1016-1026. (PMID: 27083279) Trends Biochem Sci. 1990 Jul;15(7):273-6. (PMID: 2098005) Arthritis Rheum. 2012 Oct;64(10):3129-38. (PMID: 22674488) J Exp Med. 2015 May 4;212(5):607-17. (PMID: 25918343) Immunity. 2003 May;18(5):687-98. (PMID: 12753745) J Biol Chem. 2000 Jul 7;275(27):20436-43. (PMID: 10777477) Lancet. 2011 Jun 18;377(9783):2138-49. (PMID: 21684384) Mucosal Immunol. 2014 Sep;7(5):1209-20. (PMID: 24549276) Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2995-3000. (PMID: 11867742) Diabetes Metab Res Rev. 1999 May-Jun;15(3):181-5. (PMID: 10441040) Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4571-6. (PMID: 17360565) Mod Rheumatol. 2017 May;27(3):441-447. (PMID: 27585642) Diabetes Care. 1996 Dec;19(12):1357-63. (PMID: 8941464) |
| فهرسة مساهمة: | Keywords: HDAC inhibitor (histone deacetylase inhibitor); T cells; acetylation; juvenile idiopathic arthritis (JIA); tolerance |
| المشرفين على المادة: | 0 (Histone Deacetylase Inhibitors) 0 (Histones) |
| تواريخ الأحداث: | Date Created: 20190223 Date Completed: 20200106 Latest Revision: 20200309 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC6374297 |
| DOI: | 10.3389/fimmu.2019.00151 |
| PMID: | 30792714 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!